Get the Stockscreener App
31.63
1.31%
0.41
Alkermes Plc stock is traded at $31.63, with a volume of 2.41M.
It is up +1.31% in the last 24 hours and up +12.72% over the past month.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
See More
Previous Close:
$31.22
Open:
$31.38
24h Volume:
2.41M
Relative Volume:
1.05
Market Cap:
$5.22B
Revenue:
$1.51B
Net Income/Loss:
$333.35M
P/E Ratio:
16.22
EPS:
1.95
Net Cash Flow:
$315.22M
1W Performance:
+6.64%
1M Performance:
+12.72%
6M Performance:
+8.32%
1Y Performance:
+6.32%
1-Day Range:
$31.15
$31.87
1-Week Range:
$28.93
$31.96
52-Week Range:
$25.16
$36.45
Alkermes Plc Stock (ALKS) Company Profile
Name
Alkermes Plc
Sector
Phone
00-353-1-772-8000
Address
CONNAUGHT HOUSE, DUBLIN 4
Compare ALKS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
31.63 | 5.15B | 1.51B | 333.35M | 315.22M | 1.95 |
|
ZTS
Zoetis Inc
|
124.65 | 55.21B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.16 | 51.59B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.83 | 43.51B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.76 | 37.11B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
464.93 | 20.32B | 3.08B | 1.24B | 1.07B | 25.61 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-11-25 | Initiated | Truist | Buy |
| Sep-26-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Sep-03-25 | Initiated | Wells Fargo | Overweight |
| Jul-15-25 | Initiated | Goldman | Buy |
| Jun-17-25 | Upgrade | UBS | Neutral → Buy |
| May-28-25 | Initiated | Needham | Buy |
| Mar-13-25 | Initiated | RBC Capital Mkts | Sector Perform |
| Mar-04-25 | Upgrade | UBS | Sell → Neutral |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Nov-05-24 | Upgrade | Stifel | Hold → Buy |
| Jun-17-24 | Initiated | TD Cowen | Buy |
| Mar-19-24 | Initiated | Robert W. Baird | Outperform |
| Feb-20-24 | Downgrade | UBS | Neutral → Sell |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Oct-24-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-17-23 | Initiated | UBS | Neutral |
| Nov-03-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-14-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-16-22 | Initiated | Piper Sandler | Neutral |
| Apr-22-22 | Resumed | Goldman | Buy |
| Apr-20-22 | Initiated | Goldman | Buy |
| Jan-27-22 | Upgrade | Cantor Fitzgerald | Hold → Overweight |
| Dec-01-21 | Initiated | Citigroup | Neutral |
| Oct-07-21 | Upgrade | Jefferies | Hold → Buy |
| Sep-02-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Oct-15-20 | Upgrade | Mizuho | Neutral → Buy |
| Jul-30-20 | Downgrade | Goldman | Neutral → Sell |
| Feb-14-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Feb-14-20 | Reiterated | H.C. Wainwright | Neutral |
| Feb-14-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Jan-31-20 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Sep-05-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jul-15-19 | Upgrade | Goldman | Sell → Neutral |
| May-31-19 | Initiated | H.C. Wainwright | Neutral |
| May-01-19 | Downgrade | Citigroup | Buy → Neutral |
| Dec-19-18 | Downgrade | Goldman | Neutral → Sell |
| Dec-14-18 | Initiated | Wolfe Research | Underperform |
| Dec-13-18 | Downgrade | Credit Suisse | Outperform → Underperform |
| Nov-05-18 | Initiated | Piper Jaffray | Neutral |
| Aug-07-18 | Initiated | Stifel | Hold |
| Jun-21-18 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jun-06-18 | Initiated | B. Riley FBR, Inc. | Buy |
| May-16-18 | Upgrade | Citigroup | Neutral → Buy |
| May-11-18 | Initiated | BofA/Merrill | Buy |
View All
Alkermes Plc Stock (ALKS) Latest News
Alkermes Receives FDA Breakthrough Therapy Designation for Alixorexton, Potentially Accelerating Development - Intellectia AI
Alkermes (ALKS) Is Up 6.6% After FDA Breakthrough Tag for Narcolepsy Drug Alixorexton - Yahoo! Finance Canada
Aug Final Week: Is Alkermes plc benefiting from interest rate changesJobs Report & Short-Term High Return Ideas - baoquankhu1.vn
Recap Report: Can Alkermes plc stock outperform in a bear market - baoquankhu1.vn
Erasca Stock Surges 42% in a Week: Here's What You Should Know - Finviz
ALKS: RBC Capital Raises Price Target to $47, Maintains 'Outperf - GuruFocus
Piper Sandler Raises Price Target for ALKS to $45, Reiterates Ov - GuruFocus
Are Medical Stocks Lagging Alkermes (ALKS) This Year? - sharewise.com
Avadel Pharmaceuticals shareholders approve $2.37B takeover bid - The Business Journals
Apellis Stock Crashes 23% in a Week: Here's What You Should Know - Finviz
Alkermes PLC (ALKS) Stock Price Up 3.16% on Jan 15 - GuruFocus
Alkermes (NASDAQ:ALKS) Rating Increased to Strong-Buy at Zacks Research - MarketBeat
Will Alkermes (ALKS) Beat Estimates Again in Its Next Earnings Report? - Finviz
Best Value Stocks to Buy for Jan.14 - The Globe and Mail
Update Report: Can inTEST Corporation scale operations efficientlySell Signal & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Improved Earnings Required Before Alkermes Plc (NASDAQ:ALKS) Shares Find Their Feet - 富途牛牛
Aug Rallies: Will Alkermes plc stock remain a Wall Street favorite2025 Volume Leaders & Momentum Based Trading Ideas - Bộ Nội Vụ
Retail Trends: Can Alkermes plc stock deliver 10 annual returnsInsider Selling & Precise Trade Entry Recommendations - Bộ Nội Vụ
Avadel Shareholders Approve Acquisition by Alkermes - Sleep Review
Alkermes Touts $10B Sleep Market as ALKS 2680 Heads to Phase 3, Avidel Deal Nears Close - Yahoo Finance
ALKS: ALKS 2680 advances to Phase 3, targeting major sleep disorders and expanding commercial reach - TradingView — Track All Markets
ALKS: ALKS 2680 advances as a potential blockbuster, driving growth and sleep medicine expansion - TradingView — Track All Markets
Avadel shareholders approve acquisition by Alkermes - Investing.com Nigeria
Alkermes (ALKS) Secures Shareholder Approval for Avadel Acquisition - GuruFocus
Avadel Shareholders Approve Acquisition by Alkermes plc - TipRanks
Avadel Pharmaceuticals Announces that Avadel Shareholders Approve the Proposed Acquisition by Alkermes - The Manila Times
Avadel Pharmaceuticals plc Approves Scheme of Arrangement for Alkermes Acquisition - Quiver Quantitative
Shareholders back Avadel sale to Alkermes after strong vote - Stock Titan
Alkermes plans Avadel acquisition to expand sleep portfolio - TipRanks
Alkermes plc (ALKS): Investor Outlook Reveals 47.29% Potential Upside Amid Robust Product Pipeline - DirectorsTalk Interviews
How to contact the Daily Bulletin - FinancialContent
Buybacks Report: What dividend safety score for Alkermes plc stock2025 Key Highlights & Smart Swing Trading Techniques - Bộ Nội Vụ
Is Alkermes plc (8AK) stock a momentum leaderJuly 2025 Weekly Recap & Stepwise Swing Trade Plans - Улправда
Is Alkermes plc stock positioned for digital transformation2025 Growth vs Value & Capital Protection Trade Alerts - Улправда
What dividend safety score for Alkermes plc stockMarket Sentiment Review & High Yield Equity Trading Tips - Улправда
Technical Reactions to ALKS Trends in Macro Strategies - Stock Traders Daily
Workboat Indexes - FinancialContent
Top Biotech Players REGN, INCY, PTCT Among Participants At J.P.Morgan Healthcare Conference 2026 - RTTNews
How FDA Breakthrough Therapy Status for Alixorexton Will Impact Alkermes (ALKS) Investors - Sahm
Will Alkermes plc stock split attract more investorsJuly 2025 Opening Moves & Free Technical Confirmation Trade Alerts - Улправда
Race For Avadel Heats Up: Alkermes Raises Offer To Secure $2.37B Deal After Lundbeck Challenge - MSN
Alkermes: Avadel Deal And Vibrance-2 Unlock Upside - Seeking Alpha
Alkermes (NASDAQ:ALKS) EVP Craig Hopkinson Sells 5,000 Shares - MarketBeat
Alkermes plcOrdinary Shares (NQ: ALKS - FinancialContent
Is Alkermes plc stock supported by innovation pipelineGold Moves & Free Accurate Trade Setup Notifications - ulpravda.ru
Is Alkermes plc stock a good choice for value investors2025 Trading Volume Trends & Free Technical Confirmation Trade Alerts - ulpravda.ru
FDA Grants Breakthrough Therapy Designation to ALKS' Narcolepsy Drug - Finviz
Alkermes plc's (NASDAQ:ALKS) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong? - simplywall.st
Why Analysts See The Alkermes (ALKS) Story Shifting After Avadel Deal And Orexin Data - Yahoo Finance
FDA Grants Alixorexton Breakthrough Therapy Designation for Narcolepsy Type 1 - Sleep Review
Is Alkermes plc (8AK) stock a top pick for value investorsTrade Performance Summary & Weekly Breakout Opportunity Watchlist - ulpravda.ru
Alkermes Plc Stock (ALKS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.30%
1.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):